IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. More Details
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has IRadimed's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IRMD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: IRMD's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: IRMD underperformed the US Medical Equipment industry which returned 19.4% over the past year.
Return vs Market: IRMD underperformed the US Market which returned 22.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is IRadimed's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StThe Returns At IRadimed (NASDAQ:IRMD) Provide Us With Signs Of What's To Come
1 month ago | Simply Wall StThis Analyst Just Downgraded Their IRadimed Corporation (NASDAQ:IRMD) EPS Forecasts
1 month ago | Simply Wall StInvestors Who Bought IRadimed (NASDAQ:IRMD) Shares Three Years Ago Are Now Up 67%
Is IRadimed undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IRMD ($24.32) is trading above our estimate of fair value ($5.38)
Significantly Below Fair Value: IRMD is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IRMD is poor value based on its PE Ratio (73.1x) compared to the US Medical Equipment industry average (48.9x).
PE vs Market: IRMD is poor value based on its PE Ratio (73.1x) compared to the US market (19.4x).
Price to Earnings Growth Ratio
PEG Ratio: IRMD is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: IRMD is overvalued based on its PB Ratio (4.9x) compared to the US Medical Equipment industry average (4.4x).
How is IRadimed forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IRMD's forecast earnings growth (55% per year) is above the savings rate (2.2%).
Earnings vs Market: IRMD's earnings (55% per year) are forecast to grow faster than the US market (21.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IRMD's revenue (15.7% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: IRMD's revenue (15.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IRMD's Return on Equity is forecast to be high in 3 years time
How has IRadimed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IRMD has a large one-off loss of $2.7M impacting its September 30 2020 financial results.
Growing Profit Margin: IRMD's current net profit margins (11.7%) are lower than last year (22.5%).
Past Earnings Growth Analysis
Earnings Trend: IRMD's earnings have grown by 1.2% per year over the past 5 years.
Accelerating Growth: IRMD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IRMD had negative earnings growth (-51%) over the past year, making it difficult to compare to the Medical Equipment industry average (0.2%).
Return on Equity
High ROE: IRMD's Return on Equity (6.5%) is considered low.
How is IRadimed's financial position?
Financial Position Analysis
Short Term Liabilities: IRMD's short term assets ($62.9M) exceed its short term liabilities ($4.8M).
Long Term Liabilities: IRMD's short term assets ($62.9M) exceed its long term liabilities ($4.9M).
Debt to Equity History and Analysis
Debt Level: IRMD is debt free.
Reducing Debt: IRMD had no debt 5 years ago.
Debt Coverage: IRMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IRMD has no debt, therefore coverage of interest payments is not a concern.
What is IRadimed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IRMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IRMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IRMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IRMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IRMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Roger Susi (67 yo)
Mr. Roger E. Susi serves as President and Chief Executive Officer of IRadimed Corporation since May 28, 2020. He founded IRadimed Corporation in 2004 and has been its Chairman of the Board since June 10, 2...
CEO Compensation Analysis
Compensation vs Market: Roger's total compensation ($USD488.46K) is below average for companies of similar size in the US market ($USD1.14M).
Compensation vs Earnings: Roger's compensation has been consistent with company performance over the past year.
|CFO & Secretary||7yrs||US$587.75k||0.17% |
|Vice President of Sales||0.92yr||no data||no data|
|Controller||0.92yr||no data||no data|
Experienced Management: IRMD's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
|Independent Director||1.5yrs||US$179.91k||0.11% |
|Independent Director||4.75yrs||US$152.49k||0.13% |
|Independent Director||6.92yrs||US$154.99k||0.10% |
Experienced Board: IRMD's board of directors are considered experienced (4.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.8%.
IRadimed Corporation's company bio, employee growth, exchange listings and data sources
- Name: IRadimed Corporation
- Ticker: IRMD
- Exchange: NasdaqCM
- Founded: 1992
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$294.837m
- Shares outstanding: 12.27m
- Website: https://www.iradimed.com
Number of Employees
- IRadimed Corporation
- 1025 Willa Springs Drive
- Winter Springs
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IRMD||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Jul 2014|
|46K||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Jul 2014|
|46K||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jul 2014|
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationa...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/02 23:03|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.